1. Home
  2. MNMD vs PKST Comparison

MNMD vs PKST Comparison

Compare MNMD & PKST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MNMD
  • PKST
  • Stock Information
  • Founded
  • MNMD 2019
  • PKST 2008
  • Country
  • MNMD United States
  • PKST United States
  • Employees
  • MNMD N/A
  • PKST N/A
  • Industry
  • MNMD Pharmaceuticals and Biotechnology
  • PKST Real Estate Investment Trusts
  • Sector
  • MNMD Health Care
  • PKST Real Estate
  • Exchange
  • MNMD Nasdaq
  • PKST Nasdaq
  • Market Cap
  • MNMD 509.2M
  • PKST 454.7M
  • IPO Year
  • MNMD N/A
  • PKST N/A
  • Fundamental
  • Price
  • MNMD $9.61
  • PKST $12.26
  • Analyst Decision
  • MNMD Strong Buy
  • PKST Buy
  • Analyst Count
  • MNMD 7
  • PKST 2
  • Target Price
  • MNMD $24.71
  • PKST $16.00
  • AVG Volume (30 Days)
  • MNMD 1.3M
  • PKST 184.2K
  • Earning Date
  • MNMD 07-31-2025
  • PKST 08-07-2025
  • Dividend Yield
  • MNMD N/A
  • PKST 7.39%
  • EPS Growth
  • MNMD N/A
  • PKST N/A
  • EPS
  • MNMD N/A
  • PKST N/A
  • Revenue
  • MNMD N/A
  • PKST $223,891,000.00
  • Revenue This Year
  • MNMD N/A
  • PKST N/A
  • Revenue Next Year
  • MNMD N/A
  • PKST N/A
  • P/E Ratio
  • MNMD N/A
  • PKST N/A
  • Revenue Growth
  • MNMD N/A
  • PKST N/A
  • 52 Week Low
  • MNMD $4.70
  • PKST $10.14
  • 52 Week High
  • MNMD $10.49
  • PKST $16.26
  • Technical
  • Relative Strength Index (RSI)
  • MNMD 56.17
  • PKST 36.58
  • Support Level
  • MNMD $7.96
  • PKST $11.56
  • Resistance Level
  • MNMD $10.49
  • PKST $12.60
  • Average True Range (ATR)
  • MNMD 0.55
  • PKST 0.49
  • MACD
  • MNMD -0.06
  • PKST -0.19
  • Stochastic Oscillator
  • MNMD 65.22
  • PKST 28.65

About MNMD Mind Medicine (MindMed) Inc.

Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).

About PKST Peakstone Realty Trust

Peakstone Realty Trust is an internally managed, publicly registered real estate investment trust (REIT) that owns and operates predominately single-tenant industrial and office properties with creditworthy tenants and long-term leases. Peakstone's portfolio consists of newer vintage, and well-located real estate assets in majorly high-growth coastal and sunbelt markets. The company has two reportable segments: Industrial and Office. The Industrial segment consists of industrial outdoor storage properties which have a low building-to-land ratio, or low coverage, maximizing yard space for the display, movement, and storage of materials and equipment. The Office segment includes office, R&D and data center properties.

Share on Social Networks: